1. Potential application of silver nanoparticles to control the infectivity of Rift Valley fever virus in vitro and in vivo
- Author
-
Gema Lorenzo, Josué D. Mota-Morales, Nina Bogdanchikova, Horacio Almanza-Reyes, Belén Borrego, Elena López-Gil, Alejandro Brun, Francisco Mateos, Alexey Pestryakov, Nuria de la Losa, and Vasily Burmistrov
- Subjects
0301 basic medicine ,Silver ,Rift Valley Fever ,Biomedical Engineering ,Pharmaceutical Science ,Medicine (miscellaneous) ,Bioengineering ,02 engineering and technology ,Biology ,Antiviral Agents ,Virus ,Silver nanoparticle ,Microbiology ,In vivo infection ,Mice ,03 medical and health sciences ,In vivo ,Animals ,General Materials Science ,Infectivity ,Lethal dose ,021001 nanoscience & nanotechnology ,Antivirals ,Rift Valley fever virus ,Virology ,In vitro ,Titer ,030104 developmental biology ,Vero cell ,Nanoparticles ,Molecular Medicine ,Silver nanoparticles ,0210 nano-technology - Abstract
In this work we have tested the potential antiviral activity of silver nanoparticles formulated as Argovit™ against Rift Valley fever virus (RVFV). The antiviral activity of Argovit was tested on Vero cell cultures and in type-I interferon receptor deficient mice (IFNAR -/- mice) by two different approaches (i) different dilutions of Argovit were added to previously infected cells or administrated to animals infected with a lethal dose of virus; (ii) virus was pre-incubated with different dilutions of Argovit before inoculation in mice or cells. Though the ability of silver nanoparticles to control an ongoing RVFV infection in the conditions tested was limited, the incubation of virus with Argovit before the infection led to a reduction of the infectivity titers both in vitro and in vivo. These results reveal the potential application of silver nanoparticles to control the infectivity of RVFV, which is an important zoonotic pathogen. © 2016 Elsevier Inc.
- Published
- 2016